G_genetic testing New recommendations from an international consensus conference call for genetic testing of all men with metastatic prostate cancer (PCa) and those with a family history indicative of ...

Use of a single PSA screening intervention does not reduce prostate cancer mortality after a median follow-up duration of 10 years, but does increase the detection of low-risk prostate cancer, ...

MDxHealth has 4 validated testing products with one more in the clinical pipeline. All are focused specifically on urology. The company expects to do ~$65-$70M of sales in 2023, but the valuation is a ...

In their recent study, Kerfoot and colleagues suggest that “prostatempathy”—the empathy felt by older male healthcare providers—could explain the significant association between inappropriate PSA ...

BOSTON--(BUSINESS WIRE)--Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, and Solaris Health, the nation’s leading ...

P4 Diagnostix has teamed with Pierian, a company that provides an analysis platform, to launch somatic testing for patients with prostate cancer. The partnership will further develop P4 Diagnostix’s ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...

HRR mutations are commonly of germline origin, with several real world studies suggesting a 23-44% probability of an HRR ...